|
|
Publication
|
| Title of Article |
The Effect of Cytidine Deaminase Polymorphisms on Hematotoxicity in Thai Cancer Patients Treated with Gemcitabine-based Chemotherapy |
| Date of Acceptance |
9 September 2016 |
| Journal |
| Title of Journal |
ศรีนครินทร์เวชสาร (Srinagarind Medical Journal) |
| Standard |
TCI |
| Institute of Journal |
คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น |
| ISBN/ISSN |
0857-3123 |
| Volume |
2016 |
| Issue |
31 |
| Month |
ตุลาคม |
| Year of Publication |
2016 |
| Page |
105-108 |
| Abstract |
Background: Gemcitabine (dFdC) is a high efficacy chemotherapy that used in pancreatic cancer, non-small cell lung cancer (NSCLC), ovarian cancer, bladder cancer and cholangiocarcinoma patients. However, clinical outcome and adverse effect depend on variation of gemcitabine pharmacokinetics. Moreover, 90% of gemcitabine metabolized to inactive form by cytidine deaminase enzyme (CDA). Patients who carried CDA*2 and CDA+435 C>T have high CDA activity and decrease risk of hematotoxicity. Previous report showed patients who carried CDA1/*2 and *2/*2 mutant allele decrease risk of neutropenia and thrombocytopenia from gemcitabine more than wild type group (*1/*1). In addition, NSCLC patients who carried CDA+435 CT or TT genotype have lower gemcitabine response rate than wild type.
Objective: To determine correlation between CDA polymorphisms and hematotoxicity in Thai cancer patients who treated with gemcitabine-based chemotherapy.
Methods: Seventy patients who treated with gemcitabine-based chemotherapy were enrolled in this study. CDA genotype analysis was performed by Real-time PCR technique with specific TaqMan® probe. Severity of hematotoxicity was evaluated by National Cancer Institute Common Toxicity Criteria (CTCAE) version 4.0 guideline. Severity of hematotoxicity was determined during the first 3 months after treatment. Correlation between CDA polymorphism and hematotoxicity were assessed by Binary Logistic regression test in SPSS statistic software version 17.0 (SPSS Inc., Chicago, USA)
Results: Patients who carried CDA*1/*2 and CDA + 435 CT/TT polymorphisms tended to decrease risk of neutropenia. However, correlation between CDA polymorphisms and hematotoxicity not statistically significant.
Conclusion: CDA*1/*2 and CDA + 435CT/TT SNP tended to decrease risk of hematotoxicity but no statistic significant because of small sample size. |
| Keyword |
cytidine deaminase, CDA polymorphisms, gemcitabine, hematotoxicity |
| Author |
|
| Reviewing Status |
มีผู้ประเมินอิสระ |
| Status |
ตีพิมพ์แล้ว |
| Level of Publication |
ชาติ |
| citation |
false |
| Part of thesis |
true |
| Attach file |
|
| Citation |
0
|
|
|
|
|
|
|
|
|
Journal Publication
ไทย